Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences (XBIO)
NASDAQ:XBIO
XBIO Stock Chart & Stats
$2.21
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.21
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$5.20M
Enterprise Value-$621.18K
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Mar 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.02
Price to Sales (P/S)2.46
P/FCF Ratio-2.18
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-0.22
Enterprise Value/Gross Profit-0.22
Enterprise Value/Ebitda0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Bulls Say, Bears Say
Bulls Say
Conservative Leverage (no Debt)Zero reported debt is a durable financial strength: it lowers fixed obligations and bankruptcy risk, preserving optionality to fund R&D through equity, partnerships or milestone deals. This structural flexibility supports continued investment in clinical programs without near-term debt servicing.
Top-line ImprovementSustained revenue growth (~17% TTM) indicates improving commercial or collaboration receipts and validates program progress. Durable revenue momentum helps extend runway, supports incremental R&D spend, and reduces absolute reliance on external financing if continued over coming quarters.
Focused Oncology R&D PipelineA clear focus on oncology and DNMT1-targeted programs aligns with structural demand for novel cancer therapies. For a biotech, a specialized pipeline creates potential high-value milestones, partner interest, and licensing opportunities that can materially alter long-term cash flows when clinical progress is achieved.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow (~-$2.7M TTM) is a durable weakness: ongoing cash burn erodes liquidity, forces reliance on external capital, and increases dilution risk. Without material revenue scaling or financing, this constrains multi-quarter execution of clinical programs.
Ongoing Net Losses And Negative MarginsSustained net losses and deeply negative margins show the cost base far exceeds current revenue. This structural profitability gap means the company cannot self-fund growth, heightening dependency on financings or partnerships and raising execution risk until margins materially improve.
Governance / Shareholder Engagement IssuesRepeated adjournments for lack of quorum signal weak shareholder engagement and governance frictions. This can delay critical approvals, impede timely strategic or financing actions, and create an overhang that complicates long-term planning and counterparty confidence in partnerships or capital raises.
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $5.20M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Mar 25, 2026 which is in 19 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Nov 14, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.49 by $0.16.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.49. Following the earnings report the stock price went up 1.167%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
0.74% Mutual Funds
0.72% Other Institutional Investors
98.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---